These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21166538)

  • 1. Prevention and treatment of papillomavirus-related cancers through immunization.
    Frazer IH; Leggatt GR; Mattarollo SR
    Annu Rev Immunol; 2011; 29():111-38. PubMed ID: 21166538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus vaccine: widening the scope for cancer prevention.
    No JH; Kim MK; Jeon YT; Kim YB; Song YS
    Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Yang A; Farmer E; Lin J; Wu TC; Hung CF
    Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
    Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
    Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV vaccines: preclinical development.
    Gissmann L
    Arch Med Res; 2009 Aug; 40(6):466-70. PubMed ID: 19853186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic and therapeutic vaccination against human papillomavirus].
    Brun JL; Riethmuller D
    J Gynecol Obstet Biol Reprod (Paris); 2007 Nov; 36(7):631-41. PubMed ID: 17822860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cervical cancer through papillomavirus vaccination.
    Frazer IH
    Nat Rev Immunol; 2004 Jan; 4(1):46-54. PubMed ID: 14704767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
    Tomson TT; Roden RB; Wu TC
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming barriers to adherence to HPV vaccination recommendations.
    Dempsey AF; Davis MM
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S484-91. PubMed ID: 17203992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.